Top View
- Effect of the Angiotensin-Converting Enzyme Inhibitor
- Erratum to “Validity Assessment of Self-Reported Medication Use For
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- Supplementary Financial Data for the Year Ended- March 31, 2009
- Customs Tariff - Schedule
- Characteristics of 125I-Lodocyanopindolol Binding To
- (12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
- A-Blockade and Vasodilatation Induced by Nipradilol, Arotinolol and Labetalol in Pithed Rats
- A Systematic Review of the Blood Pressure Lowering Efficacy of Diuretics As Second-Line Therapy for Primary Hypertension
- General Information
- Progress in the Enantioseparation of -Blockers by Chromatographic Methods
- Drug Repurposing Compound Library Plus (96-Well)
- Reviews Essential Tremor: What We Can Learn from Current Pharmacotherapy
- Comparative Effects of Arotinolol, Labetalol and Propranolol on Regional Myocardial Dysfunction Induced by Flow-Limiting Coronary Stenosis in Anesthetized Dogs
- Preventive Effects of Carvedilol on Nitrate Tolerance—A Randomized, Double-Blind, Placebo-Controlled Comparative Study Between Carvedilol and Arotinolol
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Principali Interazioni Dei Farmaci Onco-Ematologici Con Farmaci, Fitoterapici Ed Alimenti
- An Application to Include Blood Pressure Lowering Drug Fixed Dose
- Drug Repurposing Compound Library (96-Well)
- United States Patent (19) 11 Patent Number: 5,932,572 Dean Et Al
- Effects of a Pure Α/Β-Adrenergic Receptor Blocker on Monocrotaline-Induced Pulmonary Arterial Hypertension with Right Ventricular Hypertrophy in Rats
- (12) United States Patent (10) Patent No.: US 7,026,360 B1 Fest0 (45) Date of Patent: Apr
- Ultraviolet-Visible Reference Spectra